Korro Bio Inc reports results for the quarter ended in March - Earnings Summary

Korro Bio

14/05/2024 22:31

* Korro Bio Inc  KRRO.OQ  reported a quarterly adjusted loss
of
$2.44​​ per share for the quarter ended in March, higher than
the same quarter last year, when the company reported EPS of
$-27.50.  The mean expectation of four analysts for the quarter
was for a loss of $2.51 per share. Wall Street expected
results to range from $-2.53 to $-2.49 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Korro Bio Inc's reported EPS for the quarter was a loss of
$2.44​.
    * The company reported a quarterly loss of $19.56 million.
    * Korro Bio Inc shares had fallen by 44.2% this quarter and
gained 4.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 8.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Korro Bio Inc is
$117.50 
This summary was machine generated from LSEG data May 14 at
09:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -2.51          -2.44          Beat
 Dec. 31 2023      -2.36          -25.65         Missed
 Sep. 30 2023      -17.72         -15.50         Beat
 Jun. 30 2023      -17.76         -15.00         Beat